Pharmaceutical companies are facing a growing crisis as the rise of at-home injectables, particularly Glucagon-like peptide-1 (GLP-1) agonists, contributes to an alarming increase in medical waste. This surge not only poses significant environmental challenges but also introduces a more insidious threat: the risk of contraband. As patients administer these medications in the comfort of their homes, the improper disposal of syringes and other medical materials creates opportunities for misuse and illegal distribution.
This situation is further complicated by the regulatory landscape, which is often ill-equipped to address the nuances of at-home drug administration. Companies must navigate a complex web of compliance requirements while ensuring that their products do not inadvertently contribute to illicit activities. The implications for quality assurance and supply chain management are profound, as firms must implement robust strategies to mitigate these risks and safeguard their reputations in an increasingly scrutinized market.
Use the database as your supply chain compass →
